SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen
- Citation:
- Pharmacogenomics vol 12 (11) 1535-1543
- Year:
- 2011
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- 1
- Parents:
- 553
- Children:
- None
- Pharmas:
- Grants:
- K12 CA090628-11, CA116201, U01 GM61388, U01 GM061388-01, R01 CA133049, K12 CA090628, U01 GM061388, P50 CA116201, R01 CA133049-04, P50 CA116201-01, CA90628
- Corr. Author:
- Authors:
- Ann M Moyer Vera J Suman Richard M Weinshilboum Rajeswari Avula John L Black Stephanie L Safgren Mary J Kuffel Matthew M Ames James N Ingle Matthew P Goetz
- Networks:
- Study
- NCCTG-N89-30-52
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- breast cancer, copy number polymorphism, CYP2C19 , pharmacogenomic, polymorphism, single nucleotide, SULT1A1 , tamoxifen